🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

1/🚀New research on psychedelics, context & brain connectivity! We analysed the largest psychedelic neuroimaging dataset to date (N=62, fMRI+EEG). Key finding: Psilocybin aligns brain activity with context, linking neural dynamics to perception. A thread 🧵👇

Big up Rebecca harding amd Leor Roseman 🦋 @leorroseman.bsky.social! Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises pubmed.ncbi.nlm.nih.gov/40281226/

Psilocin slowly nuzzling its way into the 5HT2A receptor until it finds a comfortable position deep inside... And therein the magic happens... (molecular dynamics simulation from Bright Minds Biosciences)

Great to see people reacting to my new doc #TheSettlers - a reminder that if you’re in the UK you can watch it on BBC iPlayer bbc.co.uk/iplayer/episod…

It was great to present on the launch of Psychedelic Industry UK at Breaking Convention I discussed the values, mission and objectives of the organisation and opened up a survey to gain feedback from the community who attended on our goals. We will be reporting back on these soon!

The divide between mental & physical health is the biggest mistake in medicine. Let’s undo it.

From ancient brews to modern psychedelics: David Nutt and Darren Le Baron will spend an evening discussing how humans have long sought altered states - and what this tells us about our brains, cultures, & communities. 📆 10/6 🎟️ dandelion.events/e/w5r3o The Psychedelic Society

This is a big one. Classic work by Matt Wall (@mattwall.bsky.social) and co! Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression pubmed.ncbi.nlm.nih.gov/40329640/

Escitalopram (Lexapro) blunting brain responsiveness to all categories of emotional face expression. Nicholas Fabiano, MD , one for you?

And those clinical outcomes always deserve a fresh look, especially given the way they were editorially narrativized when first published.

Important meeting in manchester - book on the DrugScience website: eventbrite.co.uk/e/psychedelics…

CPCR postdoc Sean Goldy (Sean Goldy) spoke at Centre for Psychedelic Research and Psychology at Edinburgh, presenting his program of research on psychedelics’ acute subjective effects (e.g., the emotion awe), how session facilitators might shape these, and an upcoming trial.

“Philanthropy is catalytic funding”- Tom Insel. Soooo true. And so valuable. Has made ALL the difference in #psychedelic medicine. 🙏🙏🙏

Great to have you!

The health hierarchy: SLEEP EXERCISE NUTRITION STRESS CONTROL HEALTHY RELATIONSHIPS CIRCADIAN RHYTHM ADHERENCE Bright mornings & days & dark nights = great sleep, energized focused days & overall robust mental & physical health.

New: We take a closer look at Gilgamesh's positive Phase 2a results of GM-2505 (aka bretisilocin, a serotonergic psychedelic) in major depressive disorder (MDD) & speak to company execs The results should provide a welcome catalyst for the field. psychedelicalpha.com/news/gilgamesh…

Today we announced positive topline data from our Phase 2a study of GM-2505 for Major Depressive Disorder. Read more: prnewswire.com/news-releases/…

You think you get Alan Watts—until you don’t.

New in Nature Medicine: ReSPCT "An international Delphi consensus for reporting of setting in psychedelic clinical trials" by Chloé Pronovost-Morgan, Kyle Greenway, myself, and many ReSPCT Experts. "The ReSPCT guidelines and accompanying explanatory document provide a new standard for

Twice-weekly low-dose LSD over 6 weeks did not significantly reduce ADHD symptoms in adults compared to placebo. ja.ma/3HvbY38